← All trials
NCT05195918
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2023
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Jan 19, 2022
- Last posted
- Nov 15, 2022
- Enrollment
- 50
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- Cornell UniversityCollaborator
- Cornell UniversityOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityCollaborator
- Temple UniversityCollaborator
- University of WashingtonCollaborator
- University of MichiganCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.